CD163+ macrophage infiltration reflects disease activity and early treatment response in lupus nephritis.
文献摘要
Objectives Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus, potentially leading to progressive kidney damage and end-stage kidney disease. Emerging evidence suggests that macrophages play a key role in LN pathogenesis. The aim of this study was to investigate associations between renal macrophage infiltration and clinical, histopathological, and long-term renal outcomes in LN. Methods This retrospective cohort study included 58 biopsy-proven LN patients (2002-2018), with a mean follow-up of 77 months. Immunohistochemistry for CD68, CD163, CD206, and C5aR1 macrophage markers was performed on baseline kidney biopsies. Correlations with histological features and clinical parameters such as kidney function (eGFR), proteinuria and long-term renal outcomes were analysed using correlation matrices and linear mixed models. Results CD163+ macrophage infiltration in glomerular and tubulointerstitial compartments was significantly associated with clinical and histological activity, including lower baseline eGFR, lower complement levels, more leukocyturia/erythrocyturia and higher activity index scores. Patients with high CD163+ infiltration demonstrated significantly greater improvement of eGFR and proteinuria during the first 6 months of treatment post-diagnosis. Conversely, low CD163+ infiltration was associated with increased likelihood of requiring a repeat biopsy. These associations were not observed when stratifying by LN class. CD68+ macrophages showed a similar trend. CD206+ and C5aR1+ macrophages were not associated with markers of disease activity, although high glomerular C5aR1+ infiltration was linked to repeat biopsy. None of the macrophage markers were associated with long-term outcomes such as renal flares, dialysis, or transplantation. Conclusions CD163+ macrophage infiltration at baseline is associated with active disease and early treatment response in LN, independent of received treatment. While LN class guides treatment choice, CD163+ macrophage infiltration may offer additional prognostic value regarding early therapeutic response. These findings support further investigation of CD163+ macrophages as a biomarker not only providing prognostic information but also helping guide treatment choices beyond the current LN classification system.